<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01506869</url>
  </required_header>
  <id_info>
    <org_study_id>CCEMD010</org_study_id>
    <nct_id>NCT01506869</nct_id>
  </id_info>
  <brief_title>Risk Evaluation of cAncers in Chinese diabeTic Individuals: a lONgitudinal Study</brief_title>
  <acronym>REACTION</acronym>
  <official_title>A Prospective Cohort Study on the Associations of Diabetes With Cancer Risk in Chinese Men and Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Society of Endocrinology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1: Baseline investigation (nation-wide survey)&#xD;
&#xD;
      Aims: To investigate whether diabetes and prediabetes is a risk factor for cancers of all&#xD;
      sites as well as for specific type of cancer, such as breast and colorectal cancer.&#xD;
&#xD;
      Subjects and Methods: A nation-wide survey will be carried out in 200,000-250,000 individuals&#xD;
      selected from 20-25 communities stratified according to geographic regions (northeast, north,&#xD;
      east, south central, northwest, and southwest China), degrees of urbanization (large cities&#xD;
      [Beijing, Shanghai, and provincial capitals], midsize cities, county seats, and rural&#xD;
      townships), and economic development status (as assessed on the basis of the gross domestic&#xD;
      product [GDP] for each province). A comprehensive examination including questionnaire,&#xD;
      anthropometric measurements, biochemical analysis will be performed in each study&#xD;
      participant. Diabetes and prediabetes should be diagnosed by OGTT according to the WHO 1999&#xD;
      criteria, while the diagnosis of cancer is established on the self-report questionnaire and&#xD;
      cross checking with the tumor registry or a proof of doctor's diagnosis.&#xD;
&#xD;
      Phase 2: Cohort follow-up&#xD;
&#xD;
      Aims : To examine factors that modify the risk of cancer in diabetes, prediabetes and normal&#xD;
      glucose regulation (NGR).&#xD;
&#xD;
      Subjects and Methods: To recruit and follow all type 2 diabetes, prediabetes, and&#xD;
      sex,age-matched NGR (1:1) in each community for at least 3 years. For diabetes, treatment&#xD;
      target is HbA1c â‰¤ 7.0% with treatment paradigm recommended by local guideline.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>number of participants who develop cancer during follow-up</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">200000</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Type 2 diabetes</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Prediabetes</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal glucose regulation</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and urine samples were collected and retained for biomarker analysis&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        In phase 1, 200,000-250,000 individuals selected from 20-25 communities stratified&#xD;
        according to geographic regions, degrees of urbanization, and economic development status&#xD;
        In Phase 2, 30,000-40,000 type 2 diabetes, 20,000-30,000 prediabetes, 30,000-40,000 normal&#xD;
        glucose regulation, recruited from the baseline survey&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Phase 1&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt;= 40 years old&#xD;
&#xD;
          2. Gender: males and females&#xD;
&#xD;
          3. Provide written informed consent&#xD;
&#xD;
          4. Satisfactory compliance&#xD;
&#xD;
        Phase 2&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt;= 40 and =&lt; 75 years old&#xD;
&#xD;
          2. Gender: males and females&#xD;
&#xD;
          3. Provide written informed consent&#xD;
&#xD;
          4. Satisfactory compliance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of cancer;&#xD;
&#xD;
          2. History of LADA and other autoimmunity diseases;&#xD;
&#xD;
          3. Acute diabetic complication, acidosis, etc;&#xD;
&#xD;
          4. Moderate to severe liver, kidney dysfunction, i.e. ALT/AST &gt; 2.5 times the upper limit&#xD;
             of normal range or Ccr &lt; 25ml/min;&#xD;
&#xD;
          5. Any other condition or major systemic diseases that the investigator feels would&#xD;
             interfere with trial participation or evaluation of results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guang Ning, MD,PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guang Ning, MD,PHD</last_name>
    <phone>008621 64370045</phone>
    <phone_ext>663340</phone_ext>
    <email>guangning@medmail.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Jiao-Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guang Ning, MD,PHD</last_name>
      <phone>008621 64370045</phone>
      <phone_ext>663340</phone_ext>
      <email>guangning@medmail.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>January 5, 2012</study_first_submitted>
  <study_first_submitted_qc>January 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2012</study_first_posted>
  <last_update_submitted>January 9, 2012</last_update_submitted>
  <last_update_submitted_qc>January 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Guang Ning</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

